REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study

IF 13.8 1区 医学 Q1 HEMATOLOGY
Faith E. Davies, Beth Faiman, Hayley Beer, Anne Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J. Blake Bartlett, Yi Han, Georgia Attfield, Daniel Egbase, Joseph Mikhael
{"title":"REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study","authors":"Faith E. Davies, Beth Faiman, Hayley Beer, Anne Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J. Blake Bartlett, Yi Han, Georgia Attfield, Daniel Egbase, Joseph Mikhael","doi":"10.1038/s41408-026-01609-5","DOIUrl":null,"url":null,"abstract":"Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"13 1","pages":""},"PeriodicalIF":13.8000,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-026-01609-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.
REVEAL-MM:对多发性骨髓瘤早期评估变量和标志性趋势的回顾性评估——一项基于美国索赔的病例对照研究
多发性骨髓瘤(MM)经常表现出与其他常见病症重叠的非特异性症状,通常导致诊断延迟和较差的临床结果。虽然MM的诊断延迟是公认的,但在MM诊断之前的医疗保健利用模式并没有很好地定义。这项回顾性、1:1匹配的病例对照研究使用了9466名美国行政索赔患者的数据来识别MM的早期信号,并评估这些数据是否可用于在正式诊断之前预测MM风险个体。在诊断前两年内的12、9和6个月对所有诊断、程序、处方和医生访问索赔进行评估。可解释的预测模型(LASSO和Random Forest)早在诊断前12个月就确定了与MM相关的不同遭遇模式。随着诊断的临近,所有模型的预测性能都有所提高,机器学习模型在6个月时达到峰值曲线下面积(AUC) 0.826。与典型MM表现一致的声称,包括贫血,肌肉骨骼和m蛋白相关测试,在MM诊断之前更常见。这些发现表明,常规收集的索赔数据可以支持早期识别和评估有MM风险的个体,从而实现更及时的诊断和改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.70
自引率
2.30%
发文量
153
审稿时长
>12 weeks
期刊介绍: Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书